VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.6779
+0.0013 (0.19%)
At close: May 21, 2026, 4:00 PM EDT
0.6775
-0.0004 (-0.06%)
After-hours: May 21, 2026, 7:53 PM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
$45,400
Profits / Employee
-$2,145,700
Market Cap
22.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | -3 | -23.08% | 10 | 0 |
| Dec 31, 2024 | 13 | 3 | 30.00% | 13 | 0 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 10 | 0 |
| Dec 31, 2022 | 12 | -16 | -57.14% | 12 | 0 |
| Dec 31, 2021 | 28 | -78 | -73.58% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Werewolf Therapeutics | 39 |
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| Sensei Biotherapeutics | 15 |
| Skye Bioscience | 12 |
| AEON Biopharma | 8 |
| Traws Pharma | 7 |
VYNE News
- 6 days ago - VYNE Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - VYNE Therapeutics Annual report: Q4 2025 - Filings
- 5 months ago - VYNE Therapeutics Transcript: M&A Announcement - Transcripts
- 5 months ago - VYNE Therapeutics Press release: M&A Announcement - Filings
- 5 months ago - VYNE Therapeutics, Yarrow Bioscience enter merger agreement - TheFly
- 5 months ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Proxy statement: Proxy Filing - Filings
- 7 months ago - VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year - TheFly